Transforming how we edit genes with modular base editing and AI-designed enzymes

As base editing moves towards broader therapeutic adoption, programs face expanding target diversity, mutation-specific requirements, and delivery constraints. But these factors should not have to compromise precision and safety. Meanwhile with the adoption of AI, the bottleneck is no longer enzyme availability, but whether your editing platform can adapt.

Discover how modular base editing and AI-designed enzymes can help to solve the precision-safety tradeoff in this informative white paper.

You'll learn:

• Why fixed enzyme-nuclease fusions struggle to absorb rapid AI-driven innovation
• How modular editing platforms support editor-specific optimization without sacrificing mechanistic consistency
• Data of AI-designed adenine deaminases tested with iPSCs
• Regulatory advantages of modular editing platforms under the FDA's "plausible mechanism pathway"

The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.